Catherine A Foss1,2, Donika Plyku1, Alvaro A Ordonez2,3, Julian Sanchez-Bautista2,3, Hailey B Rosenthal1, Il Minn1, Martin A Lodge1, Martin G Pomper1,2, George Sgouros1, Sanjay K Jain4,2,3. 1. Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2. Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, Maryland; and. 3. Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland. 4. Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland sjain5@jhmi.edu.
Abstract
Whole-body PET/CT was performed using 124I-DPA-713, a radioligand for the 18-kDa translocator protein (TSPO), to determine biodistribution and radiation dosimetry. Methods: Healthy subjects aged 18-65 y underwent whole-body PET/CT either at 4, 24, and 48 h or at 24, 48, and 72 h after intravenous injection of 124I-DPA-713. Time-activity curves were generated and used to calculate organ time-integrated activity coefficients for each subject. The resulting time-integrated activity coefficients provided input data for calculation of organ absorbed doses and effective dose for each subject using OLINDA. Subjects were genotyped for the TSPO polymorphism rs6971, and plasma protein binding of 124I-DPA-713 was measured. Results: Three male and 3 female adults with a mean age of 40 ± 19 y were imaged. The mean administered activity and mass were 70.5 ± 5.1 MBq (range, 62.4-78.1 MBq) and 469 ± 34 ng (range, 416-520 ng), respectively. There were no adverse or clinically detectable pharmacologic effects in any of the 6 subjects. No changes in vital signs, laboratory values, or electrocardiograms were observed. 124I-DPA-713 cleared rapidly (4 h after injection) from the lungs, with hepatic elimination and localization to the gastrointestinal tract. The mean effective dose over the 6 subjects was 0.459 ± 0.127 mSv/MBq, with the liver being the dose-limiting organ (0.924 ± 0.501 mGy/MBq). The percentage of free radiotracer in blood was approximately 30% at 30 and 60 min after injection. Conclusion: 124I-DPA-713 clears rapidly from the lungs, with predominantly hepatic elimination, and is safe and well tolerated in healthy adults.
Whole-body PET/CT was performed using 124I-DPA-713, a radioligand for the 18-kDa translocator protein (TSPO), to determine biodistribution and radiation dosimetry. Methods: Healthy subjects aged 18-65 y underwent whole-body PET/CT either at 4, 24, and 48 h or at 24, 48, and 72 h after intravenous injection of 124I-DPA-713. Time-activity curves were generated and used to calculate organ time-integrated activity coefficients for each subject. The resulting time-integrated activity coefficients provided input data for calculation of organ absorbed doses and effective dose for each subject using OLINDA. Subjects were genotyped for the TSPO polymorphism rs6971, and plasma protein binding of 124I-DPA-713 was measured. Results: Three male and 3 female adults with a mean age of 40 ± 19 y were imaged. The mean administered activity and mass were 70.5 ± 5.1 MBq (range, 62.4-78.1 MBq) and 469 ± 34 ng (range, 416-520 ng), respectively. There were no adverse or clinically detectable pharmacologic effects in any of the 6 subjects. No changes in vital signs, laboratory values, or electrocardiograms were observed. 124I-DPA-713 cleared rapidly (4 h after injection) from the lungs, with hepatic elimination and localization to the gastrointestinal tract. The mean effective dose over the 6 subjects was 0.459 ± 0.127 mSv/MBq, with the liver being the dose-limiting organ (0.924 ± 0.501 mGy/MBq). The percentage of free radiotracer in blood was approximately 30% at 30 and 60 min after injection. Conclusion:124I-DPA-713 clears rapidly from the lungs, with predominantly hepatic elimination, and is safe and well tolerated in healthy adults.
Authors: Jennifer M Coughlin; Yuchuan Wang; Shuangchao Ma; Chen Yue; Pearl K Kim; Ashley V Adams; Heidi V Roosa; Kenneth L Gage; Marigo Stathis; Rana Rais; Camilo Rojas; Jennifer L McGlothan; Crystal C Watkins; Ned Sacktor; Tomas R Guilarte; Yun Zhou; Akira Sawa; Barbara S Slusher; Brian Caffo; Michael Kassiou; Christopher J Endres; Martin G Pomper Journal: J Neurovirol Date: 2014-02-25 Impact factor: 2.643
Authors: Howard J Huang; Warren Isakow; Derek E Byers; Jacquelyn T Engle; Elizabeth A Griffin; Debra Kemp; Steven L Brody; Robert J Gropler; J Philip Miller; Wenhua Chu; Dong Zhou; Richard A Pierce; Mario Castro; Robert H Mach; Delphine L Chen Journal: J Nucl Med Date: 2014-12-18 Impact factor: 10.057
Authors: Rainer Rupprecht; Vassilios Papadopoulos; Gerhard Rammes; Thomas C Baghai; Jinjiang Fan; Nagaraju Akula; Ghislaine Groyer; David Adams; Michael Schumacher Journal: Nat Rev Drug Discov Date: 2010-12 Impact factor: 84.694
Authors: Wei Han; Rinat Zaynagetdinov; Fiona E Yull; Vasiliy V Polosukhin; Linda A Gleaves; Harikrishna Tanjore; Lisa R Young; Todd E Peterson; H Charles Manning; Lawrence S Prince; Timothy S Blackwell Journal: Am J Respir Cell Mol Biol Date: 2015-07 Impact factor: 6.914
Authors: Winnie Wai-Ying Kam; Steven R Meikle; Hong Zhou; Yu Zheng; Julie M Blair; Marcus Seibel; Colin R Dunstan; Richard B Banati Journal: PLoS One Date: 2012-01-25 Impact factor: 3.240
Authors: Catherine A Foss; Alvaro A Ordonez; Ravi Naik; Deepankar Das; Andrew Hall; Yunkou Wu; Robert F Dannals; Sanjay K Jain; Martin G Pomper; Andrew G Horti Journal: Eur J Nucl Med Mol Imaging Date: 2022-06-17 Impact factor: 10.057
Authors: Filipa Mota; Alvaro A Ordonez; George Firth; Camilo A Ruiz-Bedoya; Michelle T Ma; Sanjay K Jain Journal: J Med Chem Date: 2020-02-21 Impact factor: 7.446
Authors: Alvaro A Ordonez; Elizabeth W Tucker; Carolyn J Anderson; Claire L Carter; Shashank Ganatra; Deepak Kaushal; Igor Kramnik; Philana L Lin; Cressida A Madigan; Susana Mendez; Jianghong Rao; Rada M Savic; David M Tobin; Gerhard Walzl; Robert J Wilkinson; Karen A Lacourciere; Laura E Via; Sanjay K Jain Journal: J Clin Invest Date: 2021-03-01 Impact factor: 14.808
Authors: Camilo A Ruiz-Bedoya; Filipa Mota; Elizabeth W Tucker; Farina J Mahmud; Maria I Reyes-Mantilla; Clara Erice; Melissa Bahr; Kelly Flavahan; Patricia de Jesus; John Kim; Catherine A Foss; Charles A Peloquin; Dima A Hammoud; Alvaro A Ordonez; Carlos A Pardo; Sanjay K Jain Journal: J Clin Invest Date: 2022-03-15 Impact factor: 14.808